MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, announced it has received a Notice of Allowance from the Canadian Intellectual Property Office for a pending patent application which covers MN-001 for the treatment of advanced nonalcoholic steatohepatitis.
